UCB: Will Cimzia Be Enough?

Cimzia's success is critical for UCB--not least to justify its $2.7 billion Celltech acquisition. But Cimzia will also be a test-case for whether mid-cap pharma can compete in biologics, particularly as the new Medicare program rolls out.

By Melanie Senior

The excitement is palpable at UCB Group 's expansive, modern headquarters just outside Brussels, Belgium. The group is about...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo